Business Insider2d
Vertex Pharmaceuticals’ non-opioid painkiller approved by FDA, Bloomberg says
17:51 EST Vertex Pharmaceuticals (VRTX)’ non-opioid painkiller approved by FDA, Bloomberg says Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
The Motley Fool7d
Is Vertex Pharmaceuticals Stock a Buy in 2025?
Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...
Yahoo Finance10d
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts
Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.
Yahoo Finance2d
Vertex Pharmaceuticals (NASDAQ:VRTX) lifts 3.2% this week, taking five-year gains to 83%
For example, the Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) share price is up 83% in the last five years, slightly above the market return. Over the last year the stock price is up ...
Business Insider2d
Vertex Pharmaceuticals up 2% at $448 after FDA Journavx approval
17:55 EST Vertex Pharmaceuticals (VRTX) up 2% at $448 after FDA Journavx approval Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
Business Insider2d
Vertex Pharmaceuticals announces FDA approval of Journavx
Vertex Pharmaceuticals (VRTX) Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the ...
Wall Street Journal2d
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals VRTX5.31%increase; green up pointing triangle rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.
Business Insider10d
Vertex Pharmaceuticals (VRTX) Receives a Hold from RBC Capital
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...
Business Insider2d
Vertex Pharmaceuticals’ non-opioid Journavx approved for pain by FDA
Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on VRTX: Vertex Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Business Insider5d
Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday. David Risinger has given his Buy rating due to a combination of factors ...
Reuters3d
US FDA approves Vertex's non-opioid painkiller
Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...